JUNO DIAGNOSTICS ANNOUNCES PRESENTATION AT CREDIT SUISSE 31ST ANNUAL HEALTHCARE CONFERENCE

SAN DIEGO, Oct. 25, 2022 /PRNewswire/ -- Juno Diagnostics™ (JunoDx™), a company focused on bringing vital health information to patients by improving access, affordability, and transparency, today announced participation in the Credit Suisse 31^st Annual Healthcare Conference, being held on November 7-10, 2022, in Rancho Palos Verdes, CA. 

JunoDx executive management will present a company overview on Wednesday, November 9th at 12:50 pm PT and will host individual investor meetings the same day.

Juno Diagnostics™ is a category-defining health company bringing vital prenatal health information to patients by combining access, affordability, and transparency. The Company's lead product, Juno Hazel™, is a non-invasive prenatal screening (NIPS) solution that simplifies sample collection and improves access to high-quality genetic testing results without the high cost, long lead times, and phlebotomy requirements of traditional NIPS. 

For more information, visit www.junodx.com and engage with us on LinkedIn.

Investor and Media Contact:

Amy Conrad
Juniper Point
amy@juniper-point.com
858-366-3243

View original content to download multimedia:https://www.prnewswire.com/news-releases/juno-diagnostics-announces-presentation-at-credit-suisse-31st-annual-healthcare-conference-301659091.html

SOURCE JunoDx